Literature DB >> 33291370

TGF-β Mediated Immune Evasion in Cancer-Spotlight on Cancer-Associated Fibroblasts.

Parisa Ghahremanifard1,2, Ayan Chanda1,2, Shirin Bonni1,2, Pinaki Bose1,2,3,4.   

Abstract

Various components of the tumor microenvironment (TME) play a critical role in promoting tumorigenesis, progression, and metastasis. One of the primary functions of the TME is to stimulate an immunosuppressive environment around the tumor through multiple mechanisms including the activation of the transforming growth factor-beta (TGF-β) signaling pathway. Cancer-associated fibroblasts (CAFs) are key cells in the TME that regulate the secretion of extracellular matrix (ECM) components under the influence of TGF-β. Recent reports from our group and others have described an ECM-related and CAF-associated novel gene signature that can predict resistance to immune checkpoint blockade (ICB). Importantly, studies have begun to test whether targeting some of these CAF-associated components can be used as a combinatorial approach with ICB. This perspective summarizes recent advances in our understanding of CAF and TGF-β-regulated immunosuppressive mechanisms and ways to target such signaling in cancer.

Entities:  

Keywords:  CAF; TGF-β; immunotherapy; tumor immune evasion

Year:  2020        PMID: 33291370      PMCID: PMC7762018          DOI: 10.3390/cancers12123650

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  83 in total

1.  Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10.

Authors:  G M O'Keefe; V T Nguyen; E N Benveniste
Journal:  Eur J Immunol       Date:  1999-04       Impact factor: 5.532

Review 2.  Non-Smad Signaling Pathways of the TGF-β Family.

Authors:  Ying E Zhang
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-02-01       Impact factor: 10.005

3.  TGF-beta1 down-regulates induced expression of both class II MHC and B7-1 on primary murine renal tubular epithelial cells.

Authors:  N Banu; C M Meyers
Journal:  Kidney Int       Date:  1999-09       Impact factor: 10.612

Review 4.  Transforming growth factor-β signaling in head and neck squamous cell carcinoma: Insights into cellular responses.

Authors:  Xin Pang; Ya-Ling Tang; Xin-Hua Liang
Journal:  Oncol Lett       Date:  2018-08-17       Impact factor: 2.967

5.  Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1.

Authors:  N Cohen; O Shani; Y Raz; Y Sharon; D Hoffman; L Abramovitz; N Erez
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

6.  Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Authors:  Daniel Öhlund; Abram Handly-Santana; Giulia Biffi; Ela Elyada; Ana S Almeida; Mariano Ponz-Sarvise; Vincenzo Corbo; Tobiloba E Oni; Stephen A Hearn; Eun Jung Lee; Iok In Christine Chio; Chang-Il Hwang; Hervé Tiriac; Lindsey A Baker; Dannielle D Engle; Christine Feig; Anne Kultti; Mikala Egeblad; Douglas T Fearon; James M Crawford; Hans Clevers; Youngkyu Park; David A Tuveson
Journal:  J Exp Med       Date:  2017-02-23       Impact factor: 14.307

Review 7.  Immune checkpoint inhibitors: recent progress and potential biomarkers.

Authors:  Pramod Darvin; Salman M Toor; Varun Sasidharan Nair; Eyad Elkord
Journal:  Exp Mol Med       Date:  2018-12-13       Impact factor: 8.718

8.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

Review 9.  TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis.

Authors:  Yang Hao; David Baker; Peter Ten Dijke
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

10.  MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation.

Authors:  Qiong Li; Daoxiang Zhang; Yongbin Wang; Pan Sun; Xiaodan Hou; James Larner; Wujun Xiong; Jun Mi
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more
  8 in total

1.  Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma.

Authors:  Beilei Liu; Xiaona Fang; Dora Lai-Wan Kwong; Yu Zhang; Krista Verhoeft; Lanqi Gong; Baifeng Zhang; Jie Chen; Qianqian Yu; Jie Luo; Ying Tang; Tuxiong Huang; Fei Ling; Li Fu; Qian Yan; Xin-Yuan Guan
Journal:  J Exp Clin Cancer Res       Date:  2022-05-25

Review 2.  Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation.

Authors:  Melanie Vogl; Anna Rosenmayr; Tomas Bohanes; Axel Scheed; Milos Brndiar; Elisabeth Stubenberger; Bahil Ghanim
Journal:  Cancers (Basel)       Date:  2021-02-06       Impact factor: 6.639

Review 3.  Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts.

Authors:  Xueke Shi; Christian D Young; Hongmei Zhou; Xiaojing Wang
Journal:  Biomolecules       Date:  2020-12-12

Review 4.  Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy.

Authors:  Hamzeh Sarvnaz; Maedeh Arabpour; Samira Molaei Ramshe; Reza Hosseini; Leila Asef-Kabiri; Hassan Yousefi; Mohammad Esmaeil Akbari; Nahid Eskandari
Journal:  Mol Cancer       Date:  2022-01-14       Impact factor: 27.401

Review 5.  Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.

Authors:  James L Gulley; Jeffrey Schlom; Mary Helen Barcellos-Hoff; Xiao-Jing Wang; Joan Seoane; Francois Audhuy; Yan Lan; Isabelle Dussault; Aristidis Moustakas
Journal:  Mol Oncol       Date:  2022-01-04       Impact factor: 7.449

6.  Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.

Authors:  Ruoyao Zou; Qidi Jiang; Tianqiang Jin; Mo Chen; Liangqing Yao; Hongda Ding
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 7.  Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment.

Authors:  Iljin Kim; Sanga Choi; Seongkyeong Yoo; Mingyu Lee; In-San Kim
Journal:  Cancers (Basel)       Date:  2022-07-07       Impact factor: 6.575

8.  Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.

Authors:  Xiaying Han; Jianxin Ye; Runzhi Huang; Yongai Li; Jianpeng Liu; Tong Meng; Dianwen Song
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.